MediciNova 将来の成長
Future 基準チェック /06
MediciNova の収益は、年間 6.1% 減少すると予測されています。EPS は、年間 減少すると予測されています4.8%。
主要情報
-6.1%
収益成長率
-4.8%
EPS成長率
Biotechs 収益成長 | 28.3% |
収益成長率 | n/a |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | 30 Sep 2024 |
今後の成長に関する最新情報
Recent updates
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Aug 28We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Apr 19MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Nov 27We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Jul 11Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation
Mar 18We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
Oct 12MediciNova to get US patent for MN-166 to treat brain cancer
Sep 15MediciNova's MN-166 to be part of study to treat Long COVID
Aug 16MediciNova begins study of parenteral formulation of MN-166
Jul 22MediciNova announces extension of BARDA contract for Ibudilast development
Jun 30We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
Mar 19MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
Nov 23MediciNova: The Pain Of A Positive Outlook
Aug 31MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study
Jun 21Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
May 15The MediciNova Riddle: Worth Unravelling
Apr 26MediciNova inks $20M securities purchase agreement with 3D Investment Partners
Jan 12MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
Dec 29MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
Dec 29業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | N/A | -12 | N/A | N/A | 1 |
12/31/2025 | N/A | -12 | N/A | N/A | 1 |
12/31/2024 | N/A | -11 | N/A | N/A | 1 |
9/30/2024 | N/A | -10 | -9 | -9 | N/A |
6/30/2024 | 1 | -8 | -9 | -9 | N/A |
3/31/2024 | 1 | -8 | -8 | -8 | N/A |
12/31/2023 | 1 | -9 | -7 | -7 | N/A |
9/30/2023 | 1 | -10 | -11 | -11 | N/A |
6/30/2023 | N/A | -12 | -12 | -12 | N/A |
3/31/2023 | N/A | -14 | -12 | -12 | N/A |
12/31/2022 | N/A | -14 | -13 | -13 | N/A |
9/30/2022 | N/A | -13 | -13 | -13 | N/A |
6/30/2022 | 0 | -13 | -13 | -13 | N/A |
3/31/2022 | 0 | -13 | -9 | -9 | N/A |
12/31/2021 | 4 | -10 | -9 | -9 | N/A |
9/30/2021 | 4 | -11 | -8 | -8 | N/A |
6/30/2021 | 4 | -11 | -9 | -9 | N/A |
3/31/2021 | 4 | -11 | -12 | -12 | N/A |
12/31/2020 | N/A | -14 | -11 | -11 | N/A |
9/30/2020 | N/A | -13 | -11 | -11 | N/A |
6/30/2020 | N/A | -12 | -9 | -9 | N/A |
3/31/2020 | N/A | -11 | -9 | -9 | N/A |
12/31/2019 | N/A | -13 | -9 | -9 | N/A |
9/30/2019 | N/A | -11 | -8 | -8 | N/A |
6/30/2019 | N/A | -16 | -8 | -8 | N/A |
3/31/2019 | N/A | -15 | -8 | -8 | N/A |
12/31/2018 | N/A | -15 | -9 | -9 | N/A |
9/30/2018 | N/A | -16 | -9 | -9 | N/A |
6/30/2018 | N/A | -13 | N/A | -9 | N/A |
3/31/2018 | N/A | -13 | N/A | -8 | N/A |
12/31/2017 | N/A | -11 | N/A | -7 | N/A |
9/30/2017 | N/A | -11 | N/A | -7 | N/A |
6/30/2017 | N/A | -10 | N/A | -7 | N/A |
3/31/2017 | N/A | -11 | N/A | -7 | N/A |
12/31/2016 | N/A | -11 | N/A | -7 | N/A |
9/30/2016 | N/A | -12 | N/A | -7 | N/A |
6/30/2016 | N/A | -11 | N/A | -7 | N/A |
3/31/2016 | N/A | -10 | N/A | -6 | N/A |
12/31/2015 | N/A | -9 | N/A | -7 | N/A |
9/30/2015 | N/A | -8 | N/A | -7 | N/A |
6/30/2015 | N/A | -9 | N/A | -7 | N/A |
3/31/2015 | N/A | -9 | N/A | -7 | N/A |
12/31/2014 | N/A | -9 | N/A | 1 | N/A |
9/30/2014 | 6 | -3 | N/A | -2 | N/A |
6/30/2014 | 6 | -3 | N/A | -2 | N/A |
3/31/2014 | 6 | -4 | N/A | -3 | N/A |
12/31/2013 | 6 | -4 | N/A | -11 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MNOV今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MNOV今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: MNOV今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MNOVの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。
高い収益成長: MNOV来年は収益がないと予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MNOVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です